Skye Bioscience (SKYE) Q2 2026 earnings summary

Executive summary

• Terminated all clinical activities for nimacimab and paused R&D due to competitive anti-obesity market and suboptimal monotherapy results; initiated cost-cutting and workforce reduction.

• Entered into a transaction agreement to acquire Redx Pharma Limited, with the combined company to operate as Fibrx Therapeutics, Inc., pending shareholder and regulatory approval.

• Instituted contingent value rights (CVRs) for legacy asset monetization and arranged concurrent financing and equity line of credit to support the transaction.

Financial highlights

• For the three months ended June 30, 2026: net loss of $10.8M, operating loss of $11.1M, and research and development expenses of $3.9M, down 73% year-over-year.

• For the six months ended June 30, 2026: net loss of $23.3M, operating loss of $23.7M, and R&D expenses of $11.9M, down 45% year-over-year.

• General and administrative expenses for the six months were $8.6M, up 2% year-over-year, mainly due to increased legal fees.

• Working capital deficit of $572K and accumulated deficit of $210.2M as of June 30, 2026.

• Cash and short-term investments totaled $10.1M at quarter end, down from $25.7M at year-end 2025.

Outlook and guidance

• Expects to continue incurring significant losses and negative cash flows through 2026.

• Ongoing operations beyond Q4 2026 depend on closing the Redx transaction or raising additional capital.

• Research and development and general administrative expenses expected to decrease further until transaction completion.